Physician profile
Jay Lutins
NPI 1396740163
$8,893.93
in general payments reported to CMS, 2019-2025
51 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $924 · 2021: $1,188 · 2022: $1,041 · 2023: $1,554 · 2024: $1,333 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,383.42 | 2019-2024 | Ams 700, Obtryx System - Curved, Ams Ambicor |
| Pfizer INC. | $1,367.37 | 2019-2025 | |
| Astellas Pharma US INC | $972.05 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Medtronic USA, INC. | $684.56 | 2019-2020 | |
| Abbvie INC. | $518.19 | 2019-2025 | |
| Medtronic, INC. | $452.48 | 2022-2025 | Interstim |
| Janssen Biotech, INC. | $330.55 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $328.90 | 2023-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $263.99 | 2020-2024 | Axonics, Bulkamid |
| Antares Pharma, INC. | $247.08 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Dendreon Pharmaceuticals LLC | $202.58 | 2019-2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $180.28 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $159.71 | 2020-2024 | Keytruda |
| Ferring Pharmaceuticals INC. | $157.32 | 2019-2025 | Adstiladrin |
| Tolmar, INC. | $136.90 | 2023-2025 | Jatenzo, Eligard |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lutins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.